Voprosy onkologii
-
Comparative Study Controlled Clinical Trial
[Neoadjuvant therapy of breast cancer using Newcastle disease virus].
The role of Newcastle disease virus and neoadjuvant therapy was assessed in 84 cases of breast cancer T1-4N0-2M0 (2005-2008). Combined use of the virus vaccine and chemotherapy (group A), therapy with the vaccine alone (group B) and chemotherapy regimen identical with that used in group A (group C) were compared. Histological pattern of tumor and stage were identified using expression of receptors of steroid hormones, oncoproteins Her2/neu and p53 as well as proliferation activity (marker Ki-67) before and after therapy. It was shown that the efficiency and safety of Newcastle disease virus (apathogenic strain La-Sotha) met specific immuno- and neoadjuvant therapy standards.